| nivolumab versus placebo | |||
| ATTRACTION-2, 2017 NCT02267343 | nivolumab at 3 mg/kg every 2 weeks versus placebo | patients with advanced gastric or gastro-oesophageal junction cancer who had been previously been treated with two or more chemotherapy regimens | double blind Japan, South Korea, and Taiwan |
| pembrolizumab versus nil | |||
| KEYNOTE-059, NCT02335411 | versus | ||
| pembrolizumab versus paclitaxel | |||
| Keynote 061, 2018 NCT02370498 | pembrolizumab versus paclitaxel | patients with advanced gastric or gastro-oesophageal junction cancer that progressed on first-line chemotherapy with a platinum and fluoropyrimidine and who had a PD-L1 CPS of 1 or higher | open label |
-
About
-
Browse pathology
|
treatment
-
Site map
-
Credits
Made with in Lyon
-
Contact us
-
Privacy policy
-
